Sirona Biochem Signs Research Collaboration Agreement with International Centre for Genetic Engineering and Biotechnology
November 10 2022 - 3:00AM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
(“
Sirona”) is pleased to announce it has entered
into a research collaboration with the International Centre for
Genetic Engineering and Biotechnology (“ICGEB”) to advance Sirona’s
antiviral library of compounds.
ICGEB will immediately begin screening the
library of compounds produced at Sirona’s subsidiary TFChem. The
work will be performed at the ICGEB’s Laboratory of Molecular
Virology located in Trieste, Italy under the direction of Dr
Alessandro Marcello, an expert in human virology. Scientists at
ICGEB will test the potential antivirals against SARS-CoV-2
(COVID-19) using specialized assays developed at the centre.
Previous assays on Sirona’s compounds (performed at another
institution) delivered inconclusive results that prevented the
company from assessing the value of the suite of compounds. To
address this problem, TFChem initiated a collaboration with Dr
Marcello’s team at the ICGEB. The testing in his laboratory is
ideally suited for this class of antiviral agents and will provide
data required to assess the potential of this program.
If the results are promising, it is the
intention of the parties to expand the collaboration to further
advance these compounds. Ultimately the collective goal is to
create new treatment options for SARS-CoV-2 and other viruses.
Sirona’s scientists at TFChem require the added expertise in
virology to advance this project and this collaboration is a
critical step for this program. An enormous unmet need remains in
finding better therapies to treat SARS-CoV-2 and numerous other
related viruses.
This initial evaluation is estimated to be
completed in approximately 12 weeks. An update will be provided
after the tests have been performed and the results have been
evaluated.
About the International Centre for
Genetic Engineering and Biotechnology
Established in 1983 as a special project of UNIDO, the
International Centre for Genetic Engineering and Biotechnology -
ICGEB is an independent intergovernmental organization with HQ in
Trieste (Italy) and with additional laboratories in New Delhi
(India) and Cape Town (South Africa). It counts almost 70 Member
States. The ICGEB is a not for profit IGO – any revenues generated
are re-invested in research and in the funding programs for
capacity building in its Member States. The Vision of the ICGEB is
to be the world’s leading intergovernmental Organization for
research, training and technology transfer in the field of Life
Sciences and Biotechnology. Its Mission is to combine scientific
research with capacity enhancement, thereby promoting sustainable
global development (www.icgeb.org).
The Molecular Virology Group in Trieste studies
the detection and molecular mechanisms of different arboviruses and
has been mainly involved in the response to the COVID-19 pandemic
providing support to the ICGEB Member countries. Activities
included in the formulation for protocols for SARS-CoV-2 molecular
and serological diagnostics, online tutorials and reagents to be
able to develop low-cost in-house assays. COVID-19 viruses
circulating in several countries have been sequenced for the first
time and made available to the scientific community. A pipeline for
testing antivirals against SARS-CoV-2 has been set-up allowing the
identification of novel drug candidates.
About Sirona Biochem
Corp.Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries:Jonathan WilliamsManaging
DirectorMomentum PRPhone: 1.450.332.6939Email:
jwilliams@momentumpr.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
---------------------------------------------
Sirona Biochem cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current expectations and
involve known and unknown risks and uncertainties. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of release of the
relevant information, unless explicitly stated otherwise. Actual
results, performance or achievement could differ materially from
those expressed in, or implied by, Sirona Biochem’s forward-looking
statements due to the risks and uncertainties inherent in Sirona
Biochem’s business including, without limitation, statements about:
the progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory approval,
producing and marketing its products; unexpected adverse side
effects or inadequate therapeutic efficacy of its products that
could delay or prevent product development or commercialization;
the scope and validity of patent protection for its products;
competition from other pharmaceutical or biotechnology companies;
and its ability to obtain additional financing to support its
operations. Sirona Biochem does not assume any obligation to update
any forward-looking statements except as required by law.
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Aug 2023 to Aug 2024